Expand all sections

Exenatide

Bydureon

Extended indication

Extension of indication to include the treatment of type 2 diabetes in adolescents and children aged

Therapeutic value

No estimate possible yet
Registration phase

Registration application pending

Product

Active substance

Exenatide
Domain

Metabolism and Endocrinology
Reason of inclusion

Indication extension
Main indication

Diabetes
Extended indication

Extension of indication to include the treatment of type 2 diabetes in adolescents and children aged 10 years and above
Proprietary name

Bydureon
Manufacturer

AstraZeneca
Route of administration

Subcutaneous
Therapeutical formulation

Injection
Budgetting framework

Extramural (GVS)

Registration

Registration route

Decentralised
ATMP

No
Submission date

August 2021
Expected Registration

June 2022
Orphan drug

No
Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.